{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:20:11Z","timestamp":1792819211140,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 \u201cAntiviral prophylaxis in patients with solid tumours and haematological malignancies\u201d focusing on herpes simplex virus and varicella zoster virus.<\/jats:p>","DOI":"10.1007\/s00277-021-04746-y","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T08:02:53Z","timestamp":1641542573000},"page":"491-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6104-3643","authenticated-orcid":false,"given":"Larissa","family":"Henze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sandherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J.","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yascha","family":"Khodamoradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Til Ramon","family":"Kiderlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alrun","family":"Seidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schmidt-Hieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"issue":"2","key":"4746_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","volume":"42","author":"S-Y Chen","year":"2014","unstructured":"Chen S-Y, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S et al (2014) Incidence of herpes zoster in patients with altered immune function. Infection 42(2):325\u2013334. https:\/\/doi.org\/10.1007\/s15010-013-0550-8","journal-title":"Infection"},{"key":"4746_CR2","doi-asserted-by":"publisher","first-page":"204993612198954","DOI":"10.1177\/2049936121989548","volume":"8","author":"I Ruiz-Camps","year":"2021","unstructured":"Ruiz-Camps I, Aguilar-Company J (2021) Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther Adv Infect Dis 8:2049936121989548. https:\/\/doi.org\/10.1177\/2049936121989548","journal-title":"Ther Adv Infect Dis"},{"key":"4746_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","volume":"67","author":"BW Teh","year":"2016","unstructured":"Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA (2016) Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer 67:21\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.025","journal-title":"Eur J Cancer"},{"issue":"2","key":"4746_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/COC.0b013e318209aa41","volume":"35","author":"HS Lee","year":"2012","unstructured":"Lee HS, Park JY, Shin SH, Kim SB, Lee JS, Lee A et al (2012) Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: incidence and risk factors. Am J Clin Oncol 35(2):146\u2013150. https:\/\/doi.org\/10.1097\/COC.0b013e318209aa41","journal-title":"Am J Clin Oncol"},{"issue":"21","key":"4746_CR5","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1212\/WNL.0b013e3182752ceb","volume":"79","author":"IL Tan","year":"2012","unstructured":"Tan IL, McArthur JC, Venkatesan A, Nath A (2012) Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology 79(21):2125\u20132132. https:\/\/doi.org\/10.1212\/WNL.0b013e3182752ceb","journal-title":"Neurology"},{"issue":"1","key":"4746_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/transplantology2010002","volume":"2","author":"J Styczynski","year":"2021","unstructured":"Styczynski J (2021) Management of herpesvirus infections in hematopoietic cell transplant recipients. Transplantology 2(1):8\u201321. https:\/\/doi.org\/10.3390\/transplantology2010002","journal-title":"Transplantology"},{"issue":"2","key":"4746_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cmi.2019.09.003","volume":"26","author":"O Beyar-Katz","year":"2020","unstructured":"Beyar-Katz O, Bitterman R, Zuckerman T, Ofran Y, Yahav D, Paul M (2020) Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis. Clin Microbiol Infect 26(2):189\u2013198. https:\/\/doi.org\/10.1016\/j.cmi.2019.09.003","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"4746_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","volume":"100","author":"M Christopeit","year":"2020","unstructured":"Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M et al (2020) Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 100(2):321\u201336. https:\/\/doi.org\/10.1007\/s00277-020-04297-8","journal-title":"Ann Hematol"},{"issue":"9","key":"4746_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","volume":"94","author":"M Sandherr","year":"2015","unstructured":"Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O et al (2015) Antiviral prophylaxis in patients with solid tumours and haematological malignancies\u2013update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 94(9):1441\u20131450. https:\/\/doi.org\/10.1007\/s00277-015-2447-3","journal-title":"Ann Hematol"},{"issue":"Suppl 7","key":"4746_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1469-0691.12041","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl 7):53\u201367. https:\/\/doi.org\/10.1111\/1469-0691.12041","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"4746_CR11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1128\/microbiolspec.DMIH2-0017-2015","volume":"4","author":"MJ Levin","year":"2016","unstructured":"Levin MJ, Weinberg A, Schmid DS (2016) Herpes simplex virus and varicella-zoster virus. Microbiol Spectrum 4(3):2015. https:\/\/doi.org\/10.1128\/microbiolspec.DMIH2-0017-2015","journal-title":"Microbiol Spectrum"},{"key":"4746_CR12","doi-asserted-by":"publisher","first-page":"CD006706","DOI":"10.1002\/14651858.CD006706.pub2","volume":"1","author":"A-M Glenny","year":"2009","unstructured":"Glenny A-M, Fernandez Mauleffinch LM, Pavitt S, Walsh T (2009) Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 1:CD006706. https:\/\/doi.org\/10.1002\/14651858.CD006706.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4746_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.prp.2004.12.003","volume":"201","author":"GW Herget","year":"2005","unstructured":"Herget GW, Riede UN, Schmitt-Gr\u00e4ff A, L\u00fcbbert M, Neumann-Haefelin D, K\u00f6hler G (2005) Generalized herpes simplex virus infection in an immunocompromised patient\u2013report of a case and review of the literature. Pathol Res Pract 201(2):123\u2013129. https:\/\/doi.org\/10.1016\/j.prp.2004.12.003","journal-title":"Pathol Res Pract"},{"issue":"2","key":"4746_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-0714.2008.00684.x","volume":"38","author":"M Djuric","year":"2009","unstructured":"Djuric M, Jankovic L, Jovanovic T, Pavlica D, Brkic S, Knezevic A et al (2009) Prevalence of oral herpes simplex virus reactivation in cancer patients: a comparison of different techniques of viral detection. J Oral Pathol Med 38(2):167\u2013173. https:\/\/doi.org\/10.1111\/j.1600-0714.2008.00684.x","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"4746_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaad.2006.02.031","volume":"55","author":"SL Spruance","year":"2006","unstructured":"Spruance SL, Bodsworth N, Resnick H, Conant M, Oeuvray C, Gao J et al (2006) Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 55(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2006.02.031","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4746_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/omcr\/omu001","volume":"2014","author":"MP Christman","year":"2014","unstructured":"Christman MP, Turbett SE, Sengupta S, Bakhadirov KU, Williamson CA, Nayak L et al (2014) Recurrence of herpes simplex encephalitis associated with temozolomide chemoradiation for malignant glioma: a case report and review of the literature. Oxf Med Case Reports 2014(1):1\u20134. https:\/\/doi.org\/10.1093\/omcr\/omu001","journal-title":"Oxf Med Case Reports"},{"issue":"2","key":"4746_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-011-0609-2","volume":"105","author":"JJ Graber","year":"2011","unstructured":"Graber JJ, Rosenblum MK, DeAngelis LM (2011) Herpes simplex encephalitis in patients with cancer. J Neurooncol 105(2):415\u2013421. https:\/\/doi.org\/10.1007\/s11060-011-0609-2","journal-title":"J Neurooncol"},{"issue":"8","key":"4746_CR18","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1308\/003588414X13946184902721","volume":"96","author":"DP Toomey","year":"2014","unstructured":"Toomey DP, Dhadda AS, Sanni LA, Cooke JP, Hartley JE (2014) Fatal herpes simplex virus hepatitis following neoadjuvant chemoradiotherapy and anterior resection for rectal cancer. Ann R Coll Surg Engl 96(8):e12\u2013e14. https:\/\/doi.org\/10.1308\/003588414X13946184902721","journal-title":"Ann R Coll Surg Engl"},{"issue":"14","key":"4746_CR19","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1177\/0956462417727194","volume":"28","author":"R Patel","year":"2017","unstructured":"Patel R, Kennedy OJ, Clarke E, Geretti A, Nilsen A, Lautenschlager S et al (2017) 2017 European guidelines for the management of genital herpes. Int J STD AIDS 28(14):1366\u20131379. https:\/\/doi.org\/10.1177\/0956462417727194","journal-title":"Int J STD AIDS"},{"issue":"5","key":"4746_CR20","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3904\/kjim.2018.469","volume":"35","author":"J Hong","year":"2020","unstructured":"Hong J, Park H-K, Park S, Lee A, Lee Y-H, Shin D-Y et al (2020) Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies. Korean J Intern Med 35(5):1188\u20131198. https:\/\/doi.org\/10.3904\/kjim.2018.469","journal-title":"Korean J Intern Med"},{"key":"4746_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1086\/514600","volume":"26","author":"RJ Whitley","year":"1998","unstructured":"Whitley RJ, Kimberlin DW, Roizman B (1998) Herpes simplex viruses. Clin Infect Diseases 26:541\u2013555","journal-title":"Clin Infect Diseases"},{"key":"4746_CR22","doi-asserted-by":"publisher","first-page":"CD009036","DOI":"10.1002\/14651858.CD009036.pub2","volume":"8","author":"L Le Cleach","year":"2014","unstructured":"Le Cleach L, Trinquart L, Do G, Maruani A, Lebrun-Vignes B, Ravaud P et al (2014) Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database Syst Rev 8:CD009036. https:\/\/doi.org\/10.1002\/14651858.CD009036.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"4746_CR23","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1086\/424519","volume":"190","author":"R Gupta","year":"2004","unstructured":"Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M et al (2004) Valacyclovir and Acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 190(8):1374\u20131381","journal-title":"J Infect Dis"},{"key":"4746_CR24","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","volume":"1","author":"AA Gershon","year":"2015","unstructured":"Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D et al (2015) Varicella zoster virus infection. Nat Rev Dis Primers 1:15016\u201315034. https:\/\/doi.org\/10.1038\/nrdp.2015.16","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"4746_CR25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/molecules26041132","volume":"26","author":"G Andrei","year":"2021","unstructured":"Andrei G, Snoeck R (2021) Advances and perspectives in the management of varicella-zoster virus infections. Molecules 26(4):1132. https:\/\/doi.org\/10.3390\/molecules26041132","journal-title":"Molecules"},{"issue":"9","key":"4746_CR26","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew AF, Ilhan O, Lee W-S, Woszczyk D, Kwak J-Y, Bowcock S et al (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 19(9):988\u20131000. https:\/\/doi.org\/10.1016\/S1473-3099(19)30163-X","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"4746_CR27","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087\u20132096. https:\/\/doi.org\/10.1056\/NEJMoa1501184","journal-title":"N Engl J Med"},{"issue":"1","key":"4746_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","volume":"22","author":"LA Habel","year":"2013","unstructured":"Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL et al (2013) The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev 22(1):82\u201390. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-0815","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"4746_CR29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","volume":"59","author":"AM Williams","year":"2018","unstructured":"Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C et al (2018) Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma 59(3):625\u2013632. https:\/\/doi.org\/10.1080\/10428194.2017.1347931","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4746_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/cid\/cis879","volume":"56","author":"MT van der Beek","year":"2013","unstructured":"van der Beek MT, Vermont CL, Bredius RGM, Marijt EWA, van der Blij-de Brouwer CS, Kroes ACM et al (2013) Persistence and antiviral resistance of varicella zoster virus in hematological patients. Clin Infect Diseases 56(3):335\u2013343. https:\/\/doi.org\/10.1093\/cid\/cis879","journal-title":"Clin Infect Diseases"},{"issue":"8","key":"4746_CR31","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1080\/10428194.2016.1267352","volume":"58","author":"KV Giridhar","year":"2017","unstructured":"Giridhar KV, Shanafelt T, Tosh PK, Parikh SA, Call TG (2017) Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. Leuk Lymphoma 58(8):1973\u20131976. https:\/\/doi.org\/10.1080\/10428194.2016.1267352","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4746_CR32","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jemermed.2015.10.035","volume":"50","author":"E Sutton","year":"2016","unstructured":"Sutton E, Lopez JJ, Dao LN, Wetter DA (2016) Disseminated herpes zoster in chronic lymphocytic leukemia. J Emerg Med 50(3):e159\u2013e160. https:\/\/doi.org\/10.1016\/j.jemermed.2015.10.035","journal-title":"J Emerg Med"},{"issue":"18","key":"4746_CR33","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1016\/j.ejca.2009.08.010","volume":"45","author":"D Yahav","year":"2009","unstructured":"Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M et al (2009) Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Euro J Cancer 45(18):3131\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2009.08.010","journal-title":"Euro J Cancer"},{"issue":"2","key":"4746_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00520-016-3477-7","volume":"25","author":"S Elad","year":"2017","unstructured":"Elad S, Ranna V, Ariyawardana A, Correa MEP, Tilly V, Nair RG et al (2017) A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Support Care Cancer 25(2):687\u2013700. https:\/\/doi.org\/10.1007\/s00520-016-3477-7","journal-title":"Support Care Cancer"},{"issue":"1","key":"4746_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/187152611794407773","volume":"11","author":"M Angarone","year":"2011","unstructured":"Angarone M (2011) Epidemiology and prevention of viral infections in patients with hematologic malignancies. Infect Disord Drug Targets 11(1):27\u201333","journal-title":"Infect Disord Drug Targets"},{"issue":"23","key":"4746_CR36","doi-asserted-by":"publisher","first-page":"8891","DOI":"10.3390\/ijerph17238891","volume":"17","author":"FW Aribi Al-Zoobaee","year":"2020","unstructured":"Aribi Al-Zoobaee FW, Yee SL, Veettil SK, Gopinath D, Maharajan MK, Menon RK (2020) Antiviral agents for the prevention and treatment of herpes simplex virus type-1 infection in clinical oncology: a network meta-analysis. Int J Environ Res Public Health 17(23):8891. https:\/\/doi.org\/10.3390\/ijerph17238891","journal-title":"Int J Environ Res Public Health"},{"key":"4746_CR37","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy Erin B, Bow Eric J, Crews J, Gleason C, Hawley DK et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 36:3043\u20133054. https:\/\/doi.org\/10.1200\/JCO.18.00374","journal-title":"J Clin Oncol"},{"key":"4746_CR38","unstructured":"Koordinatorin: Schmidt B. Virusinfektionen bei Organ- und allogen Stammzell-Transplantierten: Diagnostik, Pr\u00e4vention und Therapie: S2k-Leitlinie. AWMF Registernummer 093\u2013002. [November 30, 2020]; Available from: https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/093-002.html."},{"issue":"9","key":"4746_CR39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1086\/379043","volume":"188","author":"A Wald","year":"2003","unstructured":"Wald A, Huang ML, Carrell D, Selke S, Corey L (2003) Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 188(9):1345\u20131351. https:\/\/doi.org\/10.1086\/379043","journal-title":"J Infect Dis"},{"issue":"4","key":"4746_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jcv.2014.09.012","volume":"61","author":"MJ Levin","year":"2014","unstructured":"Levin MJ (2014) Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol 61(4):487\u2013495. https:\/\/doi.org\/10.1016\/j.jcv.2014.09.012","journal-title":"J Clin Virol"},{"issue":"12","key":"4746_CR41","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1128\/JCM.06753-11","volume":"50","author":"DA Wilson","year":"2012","unstructured":"Wilson DA, Yen-Lieberman B, Schindler S, Asamoto K, Schold JD, Procop GW (2012) Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol 50(12):4120\u20134122. https:\/\/doi.org\/10.1128\/JCM.06753-11","journal-title":"J Clin Microbiol"},{"issue":"1","key":"4746_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000351521","volume":"57","author":"SS Bhullar","year":"2014","unstructured":"Bhullar SS, Chandak NH, Purohit HJ, Taori GM, Daginawala HF, Kashyap RS (2014) Determination of viral load by quantitative real-time PCR in herpes simplex encephalitis patients. Intervirology 57(1):1\u20137. https:\/\/doi.org\/10.1159\/000351521","journal-title":"Intervirology"},{"issue":"9","key":"4746_CR43","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/bmt.2012.2","volume":"47","author":"MT van der Beek","year":"2012","unstructured":"van der Beek MT, Laheij AMGA, Raber-Durlacher JE, von dem Borne PA, Wolterbeek R, van der Blij-de Brouwer CS et al (2012) Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 47(9):1222\u20131228. https:\/\/doi.org\/10.1038\/bmt.2012.2","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4746_CR44","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1055\/s-0042-116494","volume":"76","author":"A Sauerbrei","year":"2016","unstructured":"Sauerbrei A (2016) Herpes genitalis: diagnosis, treatment and prevention. Geburtshilfe Frauenheilkd 76(12):1310\u20131317. https:\/\/doi.org\/10.1055\/s-0042-116494","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"4746_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/infdis\/jix508","volume":"217","author":"SY Park","year":"2017","unstructured":"Park SY, Kim JY, Kim J-A, Kwon J-S, Kim S-M, Jeon NY et al (2017) Diagnostic usefulness of varicella-zoster virus real-time polymerase chain reaction analysis of DNA in saliva and plasma specimens from patients with herpes zoster. J INFECT DIS 217(1):51\u201357. https:\/\/doi.org\/10.1093\/infdis\/jix508","journal-title":"J INFECT DIS"},{"issue":"6","key":"4746_CR46","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/infdis\/jir417","volume":"204","author":"AA Gershon","year":"2011","unstructured":"Gershon AA (2011) The history and mystery of VZV in saliva. J INFECT DIS 204(6):815\u2013816. https:\/\/doi.org\/10.1093\/infdis\/jir417","journal-title":"J INFECT DIS"},{"issue":"12","key":"4746_CR47","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/OLQ.0000000000000522","volume":"43","author":"M Ramchandani","year":"2016","unstructured":"Ramchandani M, Kong M, Tronstein E, Selke S, Mikhaylova A, Magaret A et al (2016) Herpes simplex virus type 1 shedding in tears and nasal and oral mucosa of healthy adults. Sex Transm Dis 43(12):756\u2013760. https:\/\/doi.org\/10.1097\/OLQ.0000000000000522","journal-title":"Sex Transm Dis"},{"issue":"6","key":"4746_CR48","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ajcp\/aqy088","volume":"150","author":"MN Stram","year":"2018","unstructured":"Stram MN, Suciu CN, Seheult JN, McCullough MA, Kader M, Wells A et al (2018) Herpes simplex virus-1 qPCR in the diagnosis of lower respiratory tract infections in organ transplant recipients and critically ill patients. Am J Clin Pathol 150(6):522\u2013532. https:\/\/doi.org\/10.1093\/ajcp\/aqy088","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"4746_CR49","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/annonc\/mdw155","volume":"27","author":"M Schmidt-Hieber","year":"2016","unstructured":"Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O et al (2016) CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 27(7):1207\u20131225. https:\/\/doi.org\/10.1093\/annonc\/mdw155","journal-title":"Ann Oncol"},{"issue":"1","key":"4746_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13054-019-2701-5","volume":"24","author":"L Schuierer","year":"2020","unstructured":"Schuierer L, Gebhard M, Ruf H-G, Jaschinski U, Berghaus TM, Wittmann M et al (2020) Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication. Crit Care 24(1):12. https:\/\/doi.org\/10.1186\/s13054-019-2701-5","journal-title":"Crit Care"},{"issue":"2","key":"4746_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/jamainternmed.2019.5713","volume":"180","author":"C-E Luyt","year":"2020","unstructured":"Luyt C-E, Forel J-M, Hajage D, Jaber S, Cayot-Constantin S, Rimmel\u00e9 T et al (2020) Acyclovir for mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: a randomized clinical trial. JAMA Intern Med 180(2):263\u2013272. https:\/\/doi.org\/10.1001\/jamainternmed.2019.5713","journal-title":"JAMA Intern Med"},{"key":"4746_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3205\/id000045","volume":"8","author":"GE Gross","year":"2020","unstructured":"Gross GE, Eisert L, Doerr HW, Fickenscher H, Knuf M, Maier P et al (2020) S2k-Leitlinie zur Diagnostik und Therapie des Zoster und der Postzosterneuralgie. GMS Infect Dis 8:1\u201331. https:\/\/doi.org\/10.3205\/id000045","journal-title":"GMS Infect Dis"},{"issue":"3","key":"4746_CR53","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jinf.2016.04.035","volume":"73","author":"A Grahn","year":"2016","unstructured":"Grahn A, Bergstr\u00f6m T, Runesson J, Studahl M (2016) Varicella-zoster virus (VZV) DNA in serum of patients with VZV central nervous system infections. J Infect 73(3):254\u2013260. https:\/\/doi.org\/10.1016\/j.jinf.2016.04.035","journal-title":"J Infect"},{"issue":"1","key":"4746_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13054-017-1731-0","volume":"21","author":"A Mirouse","year":"2017","unstructured":"Mirouse A, Vignon P, Piron P, Robert R, Papazian L, G\u00e9ri G et al (2017) Severe varicella-zoster virus pneumonia: a multicenter cohort study. Crit Care 21(1):137. https:\/\/doi.org\/10.1186\/s13054-017-1731-0","journal-title":"Crit Care"},{"issue":"2","key":"4746_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0163-4453(03)00004-5","volume":"47","author":"Y Ishizaki","year":"2003","unstructured":"Ishizaki Y, Tezuka J, Ohga S, Nomura A, Suga N, Kuromaru R et al (2003) Quantification of circulating varicella zoster virus-DNA for the early diagnosis of visceral varicella. J Infect 47(2):133\u2013138. https:\/\/doi.org\/10.1016\/s0163-4453(03)00004-5","journal-title":"J Infect"},{"issue":"3","key":"4746_CR56","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","volume":"23","author":"F Sahoo","year":"2017","unstructured":"Sahoo F, Hill JA, Xie H, Leisenring W, Yi J, Goyal S et al (2017) Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies. Biol Blood Marrow Transplant 23(3):505\u2013511. https:\/\/doi.org\/10.1016\/j.bbmt.2016.12.620","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"4746_CR57","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.bbmt.2019.04.015","volume":"25","author":"E Baumrin","year":"2019","unstructured":"Baumrin E, Cheng MP, Kanjilal S, Ho VT, Issa NC, Baden LR (2019) Severe herpes zoster requiring intravenous antiviral treatment in allogeneic hematopoietic cell transplantation recipients on standard acyclovir prophylaxis. Biol Blood Marrow Transplant 25(8):1642\u20131647. https:\/\/doi.org\/10.1016\/j.bbmt.2019.04.015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4746_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcv.2012.09.004","volume":"56","author":"MT van der Beek","year":"2013","unstructured":"van der Beek MT, Claas ECJ, van der Blij-de Brouwer CS, Morfin F, Rusman LG, Kroes ACM et al (2013) Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR. J Clin Virol 56(1):19\u201324. https:\/\/doi.org\/10.1016\/j.jcv.2012.09.004","journal-title":"J Clin Virol"},{"issue":"1","key":"4746_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1128\/AAC.44.1.207-209.2000","volume":"44","author":"H Steingrimsdottir","year":"2000","unstructured":"Steingrimsdottir H, Gruber A, Kalin M, Eksborg S (2000) Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 44(1):207\u2013209","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"4746_CR60","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1345\/aph.1A434","volume":"36","author":"DI Warkentin","year":"2002","unstructured":"Warkentin DI, Epstein JB, Campbell LM, Yip JG, Cox VC, Ransier A et al (2002) Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. Ann Pharmacother 36(10):1525\u20131531. https:\/\/doi.org\/10.1345\/aph.1A434","journal-title":"Ann Pharmacother"},{"issue":"9","key":"4746_CR61","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.bbmt.2018.04.003","volume":"24","author":"CJ Lee","year":"2018","unstructured":"Lee CJ, Savani BN, Ljungman P (2018) Varicella zoster virus reactivation in adult survivors of hematopoietic cell transplantation: how do we best protect our patients? Biol Blood Marrow Transplant 24(9):1783\u20131787. https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"4746_CR62","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906\u2013917. https:\/\/doi.org\/10.1056\/NEJMoa0801479","journal-title":"N Engl J Med"},{"issue":"12","key":"4746_CR63","first-page":"5437","volume":"32","author":"T Fukushima","year":"2012","unstructured":"Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M et al (2012) Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res 32(12):5437\u20135440","journal-title":"Anticancer Res"},{"issue":"5","key":"4746_CR64","first-page":"701","volume":"30","author":"E Usami","year":"2016","unstructured":"Usami E, Kimura M, Iwai M, Teramachi H, Yoshimura T (2016) Prophylactic efficacy against herpes zoster and costs difference between acyclovir and valaciclovir in hematological patients. In Vivo 30(5):701\u2013705","journal-title":"In Vivo"},{"issue":"2","key":"4746_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de La Serna J, El Idrissi M, Oostvogels L, Quittet P, L\u00f3pez-Jim\u00e9nez J et al (2019) Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 322(2):123\u201333. https:\/\/doi.org\/10.1001\/jama.2019.9053","journal-title":"JAMA"},{"issue":"8","key":"4746_CR66","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.31909","volume":"125","author":"P Vink","year":"2019","unstructured":"Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF et al (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer 125(8):1301\u20131312. https:\/\/doi.org\/10.1002\/cncr.31909","journal-title":"Cancer"},{"issue":"6","key":"4746_CR67","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/s41375-020-01074-4","volume":"35","author":"CS Zent","year":"2020","unstructured":"Zent CS, Brady MT, Delage C, Strawderman M, Laniewski N, Contant PN et al (2020) Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. Leukemia 35(6):1788\u20131791. https:\/\/doi.org\/10.1038\/s41375-020-01074-4","journal-title":"Leukemia"},{"issue":"2","key":"4746_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood.2020008758","volume":"137","author":"C Pleyer","year":"2021","unstructured":"Pleyer C, Ali MA, Cohen JI, Tian X, Soto S, Ahn IE et al (2021) Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood 137(2):185\u2013189. https:\/\/doi.org\/10.1182\/blood.2020008758","journal-title":"Blood"},{"issue":"9","key":"4746_CR69","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1473-3099(19)30400-1","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P (2019) Varicella zoster virus vaccine in patients with haematological malignancies. Lancet Infect Dis 19(9):921\u2013922. https:\/\/doi.org\/10.1016\/S1473-3099(19)30400-1","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"4746_CR70","doi-asserted-by":"publisher","first-page":"ofaa274","DOI":"10.1093\/ofid\/ofaa274","volume":"7","author":"S Ilyas","year":"2020","unstructured":"Ilyas S, Chandrasekar PH (2020) Preventing varicella-zoster: advances with the recombinant zoster vaccine. Open Forum Infect Dis 7(7):ofaa274. https:\/\/doi.org\/10.1093\/ofid\/ofaa274","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"4746_CR71","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1186\/s12885-019-6444-0","volume":"19","author":"T Sakoh","year":"2019","unstructured":"Sakoh T, Kanzaki M, Miyamoto A, Mochizuki S, Kakumoto T, Sato K et al (2019) Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. BMC Cancer 19(1):1220. https:\/\/doi.org\/10.1186\/s12885-019-6444-0","journal-title":"BMC Cancer"},{"issue":"8","key":"4746_CR72","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.jtho.2019.02.033","volume":"14","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, Kikuchi R, Iwai Y, Ito M, Tsukamoto H, Yamazaki K et al (2019) Varicella zoster virus encephalitis mimicking nivolumab-induced autoimmune neuropathy in a patient with lung cancer. J Thorac Oncol 14(8):e163\u2013e165. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.033","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4746_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41479-020-00079-y","volume":"13","author":"J Sumer","year":"2021","unstructured":"Sumer J, Waldeck F, Fischer N, Appenzeller C, Koster M, Fr\u00fch M et al (2021) HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors \u2014 a case report. Pneumonia (Nathan) 13(1):1. https:\/\/doi.org\/10.1186\/s41479-020-00079-y","journal-title":"Pneumonia (Nathan)"},{"issue":"11","key":"4746_CR74","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","volume":"63","author":"M Del Castillo","year":"2016","unstructured":"Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G (2016) The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63(11):1490\u20131493. https:\/\/doi.org\/10.1093\/cid\/ciw539","journal-title":"Clin Infect Dis"},{"key":"4746_CR75","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcv.2017.11.004","volume":"98","author":"MK Ramirez-Fort","year":"2018","unstructured":"Ramirez-Fort MK, Zeng J, Feily A, Ramirez-Pacheco LA, Jenrette JM, Mayhew DL et al (2018) Radiotherapy-induced reactivation of neurotrophic human herpes viruses: overview and management. J Clin Virol 98:18\u201327. https:\/\/doi.org\/10.1016\/j.jcv.2017.11.004","journal-title":"J Clin Virol"},{"issue":"1","key":"4746_CR76","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/hematology.2020000116","volume":"2020","author":"L Malpica","year":"2020","unstructured":"Malpica L, Moll S (2020) Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematol Am Soc Hematol Educ Program 2020(1):319\u2013327. https:\/\/doi.org\/10.1182\/hematology.2020000116","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"4746_CR77","doi-asserted-by":"publisher","first-page":"e1002024","DOI":"10.1371\/journal.pmed.1002024","volume":"13","author":"L Fardet","year":"2016","unstructured":"Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 13(5):e1002024. https:\/\/doi.org\/10.1371\/journal.pmed.1002024","journal-title":"PLoS Med"},{"issue":"1","key":"4746_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/bjc.1984.138","volume":"50","author":"H Anderson","year":"1984","unstructured":"Anderson H, Scarffe JH, Sutton RN, Hickmott E, Brigden D, Burke C (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Brit J Cancer 50(1):45\u20139. https:\/\/doi.org\/10.1038\/bjc.1984.138","journal-title":"Brit J Cancer"},{"key":"4746_CR79","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/bmj.310.6988.1169","volume":"310","author":"OJ Bergmann","year":"1995","unstructured":"Bergmann OJ, Ellermann-Eriksen S, Mogensesn SC, Ellegaard J (1995) Acyclovir given as prophylaxis agienst oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 310:1169\u20131172","journal-title":"BMJ"},{"key":"4746_CR80","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bmj.287.6389.384","volume":"287","author":"IM Hann","year":"1983","unstructured":"Hann IM, Prentice HG, Blacklock HA, Ross MG, Brigden D, Rosling AE et al (1983) Acyclovir prophylaxis against herpes virus infections in severly immunocompromised patients: randomised double blind trial. Br Med J (Clin REs Ed) 287:384\u2013388","journal-title":"Br Med J (Clin REs Ed)"},{"issue":"3","key":"4746_CR81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF00366060","volume":"1","author":"B L\u00f6nnqvist","year":"1993","unstructured":"L\u00f6nnqvist B, Palmblad J, Ljungman P, Grimfors G, J\u00e4rnmark M, Lerner R et al (1993) Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer 1(3):139\u201344. https:\/\/doi.org\/10.1007\/BF00366060","journal-title":"Support Care Cancer"},{"issue":"6","key":"4746_CR82","doi-asserted-by":"publisher","first-page":"773","DOI":"10.7326\/0003-4819-99-6-773","volume":"99","author":"R Saral","year":"1983","unstructured":"Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ et al (1983) Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99(6):773\u20136. https:\/\/doi.org\/10.7326\/0003-4819-99-6-773","journal-title":"Ann Intern Med"},{"issue":"3","key":"4746_CR83","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/10428194.2020.1838507","volume":"62","author":"CW Freyer","year":"2021","unstructured":"Freyer CW, Peterson CE, Man Y, Przespolewski A, Baron J, Luger SM (2021) Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia. Leuk Lymphoma 62(3):696\u2013702. https:\/\/doi.org\/10.1080\/10428194.2020.1838507","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4746_CR84","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1182\/hematology.2020000098","volume":"2020","author":"C Logan","year":"2020","unstructured":"Logan C, Koura D, Taplitz R (2020) Updates in infection risk and management in acute leukemia. Hematol Am Soc Hematol Educ Program 2020(1):135\u2013139. https:\/\/doi.org\/10.1182\/hematology.2020000098","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"23","key":"4746_CR85","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","volume":"122","author":"A-C Heine","year":"2013","unstructured":"Heine A-C, Brossart P, Wolf D (2013) Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122(23):3843\u20133844","journal-title":"Blood"},{"issue":"3","key":"4746_CR86","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A (2018) Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 93(3):339\u2013347. https:\/\/doi.org\/10.1002\/ajh.24976","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"4746_CR87","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-141260","volume":"136","author":"N Gauthier","year":"2020","unstructured":"Gauthier N, Soret-Dulphy J, Zhao L-P, De Daltro OR, Marcault C, Parquet N et al (2020) Ruxolitinib treatment is associated with increased incidence of infections and higher risk of HSV\/VZV recurrence in patients with myeloproliferative neoplasm (MPN) related myelofibrosis (MF). Blood 136(Supplement 1):8. https:\/\/doi.org\/10.1182\/blood-2020-141260","journal-title":"Blood"},{"key":"4746_CR88","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hon.2509","volume":"36","author":"N Polverelli","year":"2018","unstructured":"Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M et al (2018) Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients. Hematol Oncol 36:561\u2013569. https:\/\/doi.org\/10.1002\/hon.2509","journal-title":"Hematol Oncol"},{"key":"4746_CR89","doi-asserted-by":"publisher","unstructured":"Maschmeyer G, de Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, et al. (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia 33(4):844\u2013862. https:\/\/doi.org\/10.1038\/s41375-019-0388-x.","DOI":"10.1038\/s41375-019-0388-x"},{"issue":"4","key":"4746_CR90","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000323421","volume":"125","author":"LC Park","year":"2011","unstructured":"Park LC, Lee HS, Shin SH, Im H, Ye BJ, Song MK et al (2011) Herpesviridae viral infections following rituximab combined chemotherapy in patients with diffuse large B-cell lymphoma. Acta Haematol 125(4):230\u2013236. https:\/\/doi.org\/10.1159\/000323421","journal-title":"Acta Haematol"},{"issue":"Supplement 3","key":"4746_CR91","first-page":"200","volume":"40","author":"N Murawski","year":"2017","unstructured":"Murawski N, Amam J, Altmann B, Ziepert M, Haenel M, Viardot A et al (2017) Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapyassociated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. Oncol Res Treatment 40(Supplement 3):200","journal-title":"Oncol Res Treatment"},{"issue":"Supplement 1","key":"4746_CR92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2020-138642","volume":"136","author":"K Manos","year":"2020","unstructured":"Manos K, Lasica M, Grigg A, Di Ciaccio PR, Wong J, Chandra Sekaran U et al (2020) Prolonged lymphopenia and infection risk is mitigated by antimicrobial prophylaxis in patients with indolent non-hodgkin lymphoma (iNHL) treated with bendamustine +\/- anti-CD20 antibody: the Australasian lymphoma alliance experience. Blood 136(Supplement 1):47\u201349. https:\/\/doi.org\/10.1182\/blood-2020-138642","journal-title":"Blood"},{"issue":"4","key":"4746_CR93","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S2352-3026(21)00029-6","volume":"8","author":"S Gillessen","year":"2021","unstructured":"Gillessen S, Pl\u00fctschow A, Fuchs M, Markova J, Greil R, Topp MS et al (2021) Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol 8(4):e278\u2013e288. https:\/\/doi.org\/10.1016\/S2352-3026(21)00029-6","journal-title":"Lancet Haematol"},{"issue":"2","key":"4746_CR94","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann P, Pl\u00fctschow A, Kobe C, Greil R, Meissner J, Topp MS et al (2021) PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(2):223\u2013234. https:\/\/doi.org\/10.1016\/S1470-2045(20)30601-X","journal-title":"Lancet Oncol"},{"issue":"25","key":"4746_CR95","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"issue":"Supplement 1","key":"4746_CR96","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1182\/blood.V130.Suppl_1.3356.3356","volume":"130","author":"SB Hussaini","year":"2017","unstructured":"Hussaini SB, Chu J, Williams N, Sharma N, Benson Don M Jr, Rosko AE et al (2017) B-cell lymphoma patients have a 10% risk of shingles, 7% in cutaneous T-cell lymphoma. Blood 130(Supplement 1):3356. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3356.3356","journal-title":"Blood"},{"issue":"3","key":"4746_CR97","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/ejh.13553","volume":"106","author":"V Steingr\u00edmsson","year":"2021","unstructured":"Steingr\u00edmsson V, G\u00edslason GK, \u00deorsteinsd\u00f3ttir S, R\u00f6gnvaldsson S, Gottfre\u00f0sson M, Aspelund T et al (2021) A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. Eur J Haematol 106(3):346\u2013353. https:\/\/doi.org\/10.1111\/ejh.13553","journal-title":"Eur J Haematol"},{"issue":"23","key":"4746_CR98","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1182\/blood.V126.23.4167.4167","volume":"126","author":"JM Allen","year":"2015","unstructured":"Allen JM, Rybicki LA, Caimi PF, Jagadeesh D, Dean RM, Pohlman B et al (2015) Standard duration of varicella zoster virus prophylaxis may be inadequate to prevent viral reactivation in patients with chronic lymphocytic leukemia treated with front-line bendamustine plus rituximab. Blood 126(23):4167. https:\/\/doi.org\/10.1182\/blood.V126.23.4167.4167","journal-title":"Blood"},{"key":"4746_CR99","doi-asserted-by":"publisher","first-page":"222091","DOI":"10.1136\/bcr-2017-222091","volume":"2018","author":"R Srivastava","year":"2018","unstructured":"Srivastava R, Griswold D, Jamil MO (2018) Chronic lymphocytic leukaemia with necrotic herpetic adenitis: an elusive clinical condition. BMJ Case Rep 2018:222091. https:\/\/doi.org\/10.1136\/bcr-2017-222091","journal-title":"BMJ Case Rep"},{"issue":"5","key":"4746_CR100","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12067","volume":"159","author":"D Oscier","year":"2012","unstructured":"Oscier D, Dearden C, Eren E, Fegan C, Follows G, Hillmen P et al (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 159(5):541\u2013564. https:\/\/doi.org\/10.1111\/bjh.12067","journal-title":"Br J Haematol"},{"issue":"4","key":"4746_CR101","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.13020","volume":"100","author":"BF Tillman","year":"2018","unstructured":"Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL (2018) Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol 100(4):325\u2013334. https:\/\/doi.org\/10.1111\/ejh.13020","journal-title":"Eur J Haematol"},{"key":"4746_CR102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.idcr.2016.10.003","volume":"6","author":"I Chen","year":"2016","unstructured":"Chen I, Fohtung RB, Oughli HA, Bauer R, Mattar C, Powderly WG et al (2016) Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia. IDCases 6:79\u201382. https:\/\/doi.org\/10.1016\/j.idcr.2016.10.003","journal-title":"IDCases"},{"issue":"5","key":"4746_CR103","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J et al (2019) Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381(5):432\u2013443. https:\/\/doi.org\/10.1056\/NEJMoa1817073","journal-title":"N Engl J Med"},{"issue":"1","key":"4746_CR104","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L et al (2019) Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(1):43\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(18)30788-5","journal-title":"Lancet Oncol"},{"issue":"25","key":"4746_CR105","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425\u20132437. https:\/\/doi.org\/10.1056\/NEJMoa1509388","journal-title":"N Engl J Med"},{"issue":"26","key":"4746_CR106","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W et al (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379(26):2517\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1812836","journal-title":"N Engl J Med"},{"issue":"12","key":"4746_CR107","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S et al (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 3(12):1799\u20131807. https:\/\/doi.org\/10.1182\/bloodadvances.2018028761","journal-title":"Blood Adv"},{"issue":"3","key":"4746_CR108","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1400376","journal-title":"N Engl J Med"},{"issue":"23","key":"4746_CR109","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380(23):2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1815281","journal-title":"N Engl J Med"},{"issue":"12","key":"4746_CR110","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S et al (2018) Venetoclax- rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa1713976","journal-title":"N Engl J Med"},{"issue":"3","key":"4746_CR111","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","volume":"18","author":"AD Zelenetz","year":"2017","unstructured":"Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M et al (2017) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 18(3):297\u2013311. https:\/\/doi.org\/10.1016\/S1470-2045(16)30671-4","journal-title":"Lancet Oncol"},{"issue":"3","key":"4746_CR112","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","volume":"128","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Fowler NH (2016) Idelalisib in the management of lymphoma. Blood 128(3):331\u2013336. https:\/\/doi.org\/10.1182\/blood-2016-02-702761","journal-title":"Blood"},{"issue":"1","key":"4746_CR113","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/hematology.2020000119","volume":"2020","author":"A Hanlon","year":"2020","unstructured":"Hanlon A, Brander DM (2020) Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematol Am Soc Hematol Educ Program 2020(1):346\u2013356. https:\/\/doi.org\/10.1182\/hematology.2020000119","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"4746_CR114","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","volume":"6","author":"ST Bird","year":"2020","unstructured":"Bird ST, Tian F, Flowers N, Przepiorka D, Wang R, Jung T-H et al (2020) Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries. JAMA Oncol 6(2):248\u2013254. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3994","journal-title":"JAMA Oncol"},{"key":"4746_CR115","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2016.00317","volume":"7","author":"S S\u00e1nchez-Ram\u00f3n","year":"2016","unstructured":"S\u00e1nchez-Ram\u00f3n S, Dhalla F, Chapel H (2016) Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Front Immunol 7:317. https:\/\/doi.org\/10.3389\/fimmu.2016.00317","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"4746_CR116","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"L Drgona","year":"2018","unstructured":"Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens II: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 24(Suppl 2):S83\u2013S94. https:\/\/doi.org\/10.1016\/j.cmi.2018.03.022","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4746_CR117","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","volume":"32","author":"H Ludwig","year":"2018","unstructured":"Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P et al (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 32(7):1542\u20131560. https:\/\/doi.org\/10.1038\/s41375-018-0040-1","journal-title":"Leukemia"},{"issue":"1","key":"4746_CR118","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2141.2012.09233.x","volume":"159","author":"J Minarik","year":"2012","unstructured":"Minarik J, Pika T, Bacovsky J, Langova K, Scudla V (2012) Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol 159(1):111\u2013113. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09233.x","journal-title":"Br J Haematol"},{"issue":"10","key":"4746_CR119","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1080\/10428194.2018.1429605","volume":"59","author":"S Leng","year":"2018","unstructured":"Leng S, Lentzsch S, Shen Y, Tsai W-Y, Wright JD, Hershman DL et al (2018) Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors. Leuk Lymphoma 59(10):2465\u20132469. https:\/\/doi.org\/10.1080\/10428194.2018.1429605","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4746_CR120","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/cncr.24006","volume":"115","author":"E Vickrey","year":"2009","unstructured":"Vickrey E, Allen S, Mehta J, Singhal S (2009) Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115(1):229\u2013232. https:\/\/doi.org\/10.1002\/cncr.24006","journal-title":"Cancer"},{"issue":"17","key":"4746_CR121","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634. https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"issue":"6","key":"4746_CR122","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ejh.12749","volume":"96","author":"E Muchtar","year":"2016","unstructured":"Muchtar E, Gertz MA, Magen H (2016) A practical review on carfilzomib in multiple myeloma. Eur J Haematol 96(6):564\u2013577. https:\/\/doi.org\/10.1111\/ejh.12749","journal-title":"Eur J Haematol"},{"issue":"4","key":"4746_CR123","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.14733","volume":"178","author":"S Kumar","year":"2017","unstructured":"Kumar S, Moreau P, Hari P, Mateos M-V, Ludwig H, Shustik C et al (2017) Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Br J Haematol 178(4):571\u2013582. https:\/\/doi.org\/10.1111\/bjh.14733","journal-title":"Br J Haematol"},{"issue":"3","key":"4746_CR124","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00277-013-1951-6","volume":"93","author":"C K\u00f6nig","year":"2014","unstructured":"K\u00f6nig C, Kleber M, Reinhardt H, Knop S, W\u00e4sch R, Engelhardt M (2014) Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 93(3):479\u2013484. https:\/\/doi.org\/10.1007\/s00277-013-1951-6","journal-title":"Ann Hematol"},{"issue":"7","key":"4746_CR125","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3109\/10428194.2015.1106538","volume":"57","author":"BW Teh","year":"2016","unstructured":"Teh BW, Harrison SJ, Worth LJ, Slavin MA (2016) Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. Leuk Lymphoma 57(7):1719\u20131722. https:\/\/doi.org\/10.3109\/10428194.2015.1106538","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"4746_CR126","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Diseases 49(8):1211\u20131225. https:\/\/doi.org\/10.1086\/605664","journal-title":"Clin Infect Diseases"},{"issue":"11","key":"4746_CR127","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98(11):1753\u20131761. https:\/\/doi.org\/10.3324\/haematol.2013.089334","journal-title":"Haematologica"},{"issue":"2","key":"4746_CR128","doi-asserted-by":"publisher","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","volume":"14","author":"H Nahi","year":"2019","unstructured":"Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G et al (2019) Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE 14(2):e0211927. https:\/\/doi.org\/10.1371\/journal.pone.0211927","journal-title":"PLoS ONE"},{"issue":"6","key":"4746_CR129","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1200\/JCO.1997.15.6.2269","volume":"15","author":"OJ Bergmann","year":"1997","unstructured":"Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J (1997) Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 15(6):2269\u20132274. https:\/\/doi.org\/10.1200\/JCO.1997.15.6.2269","journal-title":"J Clin Oncol"},{"issue":"22","key":"4746_CR130","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1182\/blood.V128.22.1778.1778","volume":"128","author":"T Dang","year":"2016","unstructured":"Dang T, Ni A, Gerecitano JF Jr, Hamlin PA, Hohl TM, Kumar A et al (2016) Incidence of infectious complications associated with bendamustine and anti-CD20 monoclonal antibody combination at Memorial Sloan Kettering Cancer Center (MSKCC). Blood 128(22):1778. https:\/\/doi.org\/10.1182\/blood.V128.22.1778.1778","journal-title":"Blood"},{"issue":"Supplement 1","key":"4746_CR131","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood-2018-99-113957","volume":"132","author":"GY Vazquez","year":"2018","unstructured":"Vazquez GY, Rivera Concepcion J, Cabanillas F (2018) Incidence and risk factors for developing herpes zoster among a cohort of patients diagnosed with lymphoma at a community cancer center. Blood 132(Supplement 1):3589. https:\/\/doi.org\/10.1182\/blood-2018-99-113957","journal-title":"Blood"},{"issue":"12","key":"4746_CR132","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Byrd JC (2019) How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133(12):1298\u20131307. https:\/\/doi.org\/10.1182\/blood-2018-11-846808","journal-title":"Blood"},{"issue":"3","key":"4746_CR133","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.26717\/BJSTR.2019.14.002560","volume":"14","author":"J Attallah","year":"2019","unstructured":"Attallah J, Khan U, Sharma M, Kafri Z (2019) Disseminated herpes simplex virus type 2 after treatment with idelalisib. BJSTR 14(3):2560. https:\/\/doi.org\/10.26717\/BJSTR.2019.14.002560","journal-title":"BJSTR"},{"issue":"29","key":"4746_CR134","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","volume":"26","author":"A Chanan-Khan","year":"2008","unstructured":"Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau J-L et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26(29):4784\u20134790. https:\/\/doi.org\/10.1200\/JCO.2007.14.9641","journal-title":"J Clin Oncol"},{"issue":"2","key":"4746_CR135","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","volume":"9","author":"L Pour","year":"2009","unstructured":"Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V et al (2009) Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 9(2):151\u2013153. https:\/\/doi.org\/10.3816\/CLM.2009.n.036","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"4746_CR136","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jjco\/hyq194","volume":"41","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Kim K, Do YR, Bae SH, Yang D-H, Lee J-J (2011) Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol 41(3):353\u2013357. https:\/\/doi.org\/10.1093\/jjco\/hyq194","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"4746_CR137","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.suponc.2011.10.006","volume":"10","author":"A Swaika","year":"2012","unstructured":"Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D et al (2012) Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol 10(4):155\u2013159. https:\/\/doi.org\/10.1016\/j.suponc.2011.10.006","journal-title":"J Support Oncol"},{"issue":"19","key":"4746_CR138","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M et al (2018) Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379(19):1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1805762","journal-title":"N Engl J Med"},{"issue":"9","key":"4746_CR139","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00128071-200203090-00001","volume":"3","author":"AF Nikkels","year":"2002","unstructured":"Nikkels AF, Pi\u00e9rard GE (2002) Oral antivirals revisited in the treatment of herpes zoster: what do they accomplish? Am J Clin Dermatol 3(9):591\u2013598. https:\/\/doi.org\/10.2165\/00128071-200203090-00001","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"4746_CR140","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jdv.13957","volume":"31","author":"RN Werner","year":"2017","unstructured":"Werner RN, Nikkels AF, Marinovi\u0107 B, Sch\u00e4fer M, Czarnecka-Operacz M, Agius AM et al (2017) European consensus-based (S2k) guideline on the management of herpes zoster \u2014 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol 31(1):20\u201329. https:\/\/doi.org\/10.1111\/jdv.13957","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"4746_CR141","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s13311-016-0433-7","volume":"13","author":"MJ Bradshaw","year":"2016","unstructured":"Bradshaw MJ, Venkatesan A (2016) Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management. Neurotherapeutics 13(3):493\u2013508. https:\/\/doi.org\/10.1007\/s13311-016-0433-7","journal-title":"Neurotherapeutics"},{"issue":"4","key":"4746_CR142","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/ICU.0000000000000482","volume":"29","author":"T Kalezic","year":"2018","unstructured":"Kalezic T, Mazen M, Kuklinski E, Asbell P (2018) Herpetic eye disease study: lessons learned. Curr Opin Ophthalmol 29(4):340\u2013346. https:\/\/doi.org\/10.1097\/ICU.0000000000000482","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"4746_CR143","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/ICU.0000000000000491","volume":"29","author":"JY Li","year":"2018","unstructured":"Li JY (2018) Herpes zoster ophthalmicus: acute keratitis. Curr Opin Ophthalmol 29(4):328\u2013333. https:\/\/doi.org\/10.1097\/ICU.0000000000000491","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"4746_CR144","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/02841860802660502","volume":"48","author":"AE R\u00e4tz Bravo","year":"2009","unstructured":"R\u00e4tz Bravo AE, Hofer S, Kr\u00e4henb\u00fchl S, Ludwig C (2009) Fatal drug-drug interaction of brivudine and capecitabine. Acta Oncol 48(4):631\u2013633. https:\/\/doi.org\/10.1080\/02841860802660502","journal-title":"Acta Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04746-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04746-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04746-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T22:07:20Z","timestamp":1643839640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04746-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":144,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4746"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04746-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Larissa Henze (LH):Financing of Scientific Research: German Federal Ministry of Research and Education\u00a0(BMBF).Outside the submitted work.Christoph Buhl (CB):CB has no financial or non-financial interests to disclose.Michael Sandherr (MS):Honoraria: Roche, Bristol-Myers Squibb, Novartis.Oliver A. Cornely (OAC):OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana\/United Medical\/Knight, Hikma, MedScape, MedUpdate, Merck\/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley.Werner J. Heinz (WJH):Financing of scientific research: MSD Sharp & Dohme\/Merck and Pfizer;Other Financial Relationships: serves on the speakers\u2019 bureaus of Abbvie, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD Sharp & Dohme, and Pfizer; received travel grants from Abbvie, Alexion, Astellas, Lilly, MSD Sharp & Dohme, Novartis and Pfizer.Yascha Khodamoradi (YK):Other Financial Relationships: speaker\u2019s fee and travel grant from GILEAD Science, MSD Sharp & Dome.Til Ramon Kiderlen (TRK):Advisory Role: GSK.Honoraria: Pfizer, GSK.Financing of scientific research: Pfizer.Philipp Koehler (PK):Advisory Role and\/or Honoraria: Akademie f\u00fcr Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, Noxxon N.V., University Hospital, LMU Munich;Financing of scientific research: German Federal Ministry of Research and Education and the State of North Rhine-Westphalia, Germany;Non-financial scientific grants: Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.Outside the submitted work.Alrun Seidler (AS):AS has no financial or non-financial interests to disclose.Rosanne Sprute (RS):RS has no financial or non-financial interests to disclose.Martin Schmidt-Hieber (MSH):Advisory Role or Expert Testimony (no personal fee): Celgene GmbH, Amgen, Kite\/Pharma Gilead, Sanofi;Other Financial Relationships: financial support of educational meetings at the Carl-Thiem-Klinikum Cottbus by Janssen-Cilag GmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Novartis Pharma Oncology, Pfizer Pharma GmbH, Roche Pharma AG, Vifor Pharma Deutschland\u00a0GmbH, Celgene GmbH.Marie von Lilienfeld-Toal (MvL):Advisory Role or Expert Testimony: Celgene, Gilead, Oncopeptides, MSD, 4DPharma, Janssen, Shionogi, Pfizer.Honoraria: Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Abbvie, AstraZeneca, Pfizer.Financing of Scientific Research: German Federal Ministry of Research and Education, Deutsche Jose Carreras Leuk\u00e4mie-Stiftung, IZKF Jena, DFG (German Research Foundation), Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides.Other Financial Relationships (travel grants): Janssen, Celgene.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}